2/2
05:42 pm
dwtx
DWTX: Financing Secures Funding Through Phase 2b Data Readout [Yahoo! Finance]
Medium
Report
DWTX: Financing Secures Funding Through Phase 2b Data Readout [Yahoo! Finance]
2/2
09:17 am
dwtx
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 [Yahoo! Finance]
Medium
Report
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 [Yahoo! Finance]
2/2
08:30 am
dwtx
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
Low
Report
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
1/30
08:03 am
dwtx
Dogwood Therapeutics (NASDAQ:DWTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Dogwood Therapeutics (NASDAQ:DWTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
1/12
08:30 am
dwtx
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
Medium
Report
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
12/22
11:20 am
dwtx
Dogwood Therapeutics Says Interim Phase 2B Data Show Pain Improvement With Halneuron [Yahoo! Finance]
Low
Report
Dogwood Therapeutics Says Interim Phase 2B Data Show Pain Improvement With Halneuron [Yahoo! Finance]
12/22
11:00 am
dwtx
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain [Yahoo! Finance]
High
Report
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain [Yahoo! Finance]
12/22
10:15 am
dwtx
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
High
Report
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
12/13
01:10 am
dwtx
Dogwood Therapeutics (NASDAQ:DWTX) was downgraded by analysts at
Wall St
Medium
Report
Dogwood Therapeutics (NASDAQ:DWTX) was downgraded by analysts at
Wall St
11/26
01:14 pm
dwtx
Chemotherapy-induced Peripheral Neuropathy Treatment Market Poised for Strong Growth Throughout the Forecast Period (2025–2034) Amid Rising Chemotherapy Adoption | DelveInsight [Yahoo! Finance]
Low
Report
Chemotherapy-induced Peripheral Neuropathy Treatment Market Poised for Strong Growth Throughout the Forecast Period (2025–2034) Amid Rising Chemotherapy Adoption | DelveInsight [Yahoo! Finance]